PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer

Modern Pathology

Volumn 25, Issue 3, 2012, Pages 449-455

  Quick, Charles M ^a   Ning, Gang ^b   Bijron, Jonathan ^a   Laury, Anna ^a   Wei, Tay Seok ^c   Chen, Eleanor Y ^a   Vargas, Sara O ^d   Betensky, Rebecca A ^e   McKeon, Frank D ^b,c   Xian, Wa ^a   Crum, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

fallopian tube; ovarian cancer; oviduct; PAX2; serous cancer

Indexed keywords

TRANSCRIPTION FACTOR PAX2;

ARTICLE; CASE CONTROL STUDY; CELL GROWTH; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVIDUCT; PELVIS CANCER; PRIORITY JOURNAL; SECRETORY CELL; SECRETORY CELL OUTGROWTH;

ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBES; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PAX2 TRANSCRIPTION FACTOR; PELVIC NEOPLASMS;

EID: 84857555620     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.175     Document Type: Article

References (25)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 1993;329:1550-1559.
2. Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009;113:775-782.
3. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2005;100:58-64.
4. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006;30:230-236.
5. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007;31:161-169.
6. Salvador S, Rempel A, Soslow RA, et al. Chromosomal instability in oviduct precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and oviduct mucosal serous carcinoma. Gynecol Oncol 2008;110:408-417.
7. Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010;34:1407-1416.
8. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal oviduct. J Pathol 2006;211:26-35.
9. Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001;25:1283-1289.
10. Shaw PA, Rouzbahman M, Pizer ES, et al. Candidate serous cancer precursors in oviduct epithelium of BRCA1/2 mutation carriers. Mod Pathol 2009;22: 1133-1138.
11. Callahan MJ, Crum CP, Medeiros F, et al. Primary oviduct malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007;25:3985-3990.
12. Wei JJ, Wu J, Luan C, et al. HMGA2: a potential biomarker complement to P53 for detection of earlystage high-grade papillary serous carcinoma in oviducts. Am J Surg Pathol 2010;34:18-26.
13. Mehra K, Mehrad M, Ning G, et al. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci (Elite Ed) 2011;3: 625-634.
14. Chen EY, Mehra K, Mehrad M, et al. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Oviduct. J Pathol 2010;222:110-116.
15. Laury AR, Ning G, Quick CM, et al. Fallopian tube correlates of serous borderline tumors. Am J Surg Pathol (in press).
16. Roh MH, Yassin Y, Miron A, et al. High-grade fimbrialovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod Pathol 2010;23:1316-1324.
17. Marquez RT, Baggerly KA, Patterson AP, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 2005;11:6116-6126.
18. Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 2010;10:803-808.
19. Chivukula M, Dabbs DJ, O'Connor S, et al. PAX 2: a novel Mü llerian marker for serous papillary carcinomas to differentiate from micropapillary breast carcinoma. Int J Gynecol Pathol 2009;28:570-578.
20. Monte NM, Webster KA, Neuberg D, et al. Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer. Cancer Res 2010;70:6225-6232.
21. Tung CS, Mok SC, Tsang YT, et al. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol 2009;22: 1243-1250.
22. Vicus D, Shaw PA, Finch A, et al. Risk factors for noninvasive lesions of the oviduct in BRCA mutation carriers. Gynecol Oncol 2010;118:295-298.
23. Mehra KK, Chang MC, Folkins AK, et al. The impact of tissue block sampling on the detection of p53 signatures in fallopian tubes from women with BRCA 1 or 2 mutations (BRCA+) and controls. Mod Pathol 2010;24:152-156.
24. Fornasarig M, Valentini M, Poletti M, et al. Evaluation of the risk for metachronous colorectal neoplasms following intestinal polypectomy: a clinical, endoscopic and pathological study. Hepatogastroenterology 1998;45:1565-1572.
25. Liszka L, Pajak J, Mrowiec S, et al. Precursor lesions of early onset pancreatic cancer. Virchows Arch 2011;458: 439-451.